eligibility_summary
Eligibility: Adults ≥18 with RRMM after ≥2 lines, ECOG ≤2, life expectancy >3 mo, adequate organs, measurable disease, prior exposures allowed (CAR‑T rules), prior AEs ≤G1 (except alopecia/G2 neuropathy), consent, REMS, contraception, insurance for pom/dex. Exclude: other plasma‑cell disorders, recent tx/radiation/surgery, belantamab‑refractory, corneal disease, unstable liver/renal, neuropathy/CV risk, active infection/bleeding, HBV/HCV/HIV per limits, pregnancy/lactation, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05789303 (Phase II) tests a 4-drug regimen in relapsed/refractory multiple myeloma: 1) Belantamab mafodotin (Blenrep), an antibody–drug conjugate targeting BCMA on malignant plasma cells, internalization releases MMAF to disrupt microtubules and induce apoptosis, can also mediate ADCC/ADCP. 2) Carfilzomib (Kyprolis), a small‑molecule, irreversible 20S proteasome inhibitor, causing proteotoxic stress, blocking NF‑κB activation, and triggering apoptosis. 3) Pomalidomide (Pomalyst), an IMiD that binds cereblon to degrade Ikaros/Aiolos (IKZF1/3), enhancing T/NK‑cell function and anti‑myeloma activity. 4) Dexamethasone, a glucocorticoid inducing lymphoid apoptosis. Targets/pathways: BCMA+ plasma cells, ubiquitin–proteasome system/UPR, NF‑κB, cereblon‑IKZF1/3 axis, T/NK immune activation, glucocorticoid receptor signaling.